Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Nutr. 2014 Dec;33(6):1017-23. doi: 10.1016/j.clnu.2014.03.006. Epub 2014 Apr 4.

Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.

Author information

1
Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico.
2
Neuroimmunology Unit/Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
3
Cancer Research Unit/Instituto Nacional de Cancerología, Mexico City, Mexico.
4
Thoracic Oncology Clinic/Instituto Nacional de Cancerología, Mexico City, Mexico; Universidad Nacional Autónoma de México, Mexico City, Mexico. Electronic address: ogar@servidor.unam.mx.

Abstract

BACKGROUND:

Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects.

OBJECTIVE:

To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients.

DESIGN:

Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated.

RESULTS:

Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy (p < 0.001) and protein (p < 0.001) intake compared with control. Compared with baseline, patients receiving the ONS-EPA gained 1.6 ± 5 kg of lean body mass (LBM) compared with a loss of -2.0 ± 6 kg in the control (p = 0.01). Fatigue, loss of appetite and neuropathy decreased in the ONS-EPA group (p ≤ 0.05). There was no difference in response rate or overall survival between groups.

CONCLUSION:

Patients with NSCLC receiving ONS-EPA significantly improves energy and protein intake, body composition. and decreased fatigue, loss of appetite and neuropathy. Registered with ClinicalTrials.gov (NCT01048970).

KEYWORDS:

Eicosapentaenoic acid; Health-related quality of life; Non-small cell lung cancer; Nutritional status

PMID:
24746976
DOI:
10.1016/j.clnu.2014.03.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center